Rovaleucel is under clinical development by Tessa Therapeutics and currently in Phase III for Nasopharyngeal Cancer. According to GlobalData, Phase III drugs for Nasopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rovaleucel LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rovaleucel overview
Rovaleucel (TT-10) is under development for the treatment of EBV positive nasopharyngeal cancer and lymphoproliferative diseases. It is administrated intravenously. The therapeutic candidate constitutes autologous EBV specific cytotoxic T lymphocytes. They act by targeting cells expressing LMP1 and LMP2. The therapeutic candidate is developed based on Virus-Specific T Cell (VST) technology. It was under development for the treatment of gastric cancer.
See Also:
Tessa Therapeutics overview
Tessa Therapeutics is a clinical-stage biotechnology company that discovers, develops, and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response and identify and exterminate cancer cells. The company provides products for cancers including gastric carcinoma, cervical, nasopharyngeal, head, oropharyngeal, and neck cancer. It harnesses virus-specific T cell (VST) technology for the treatment of solid tumors. Tessa Therapeutics is also extending its VST platform and treat an array of solid tumors through combinatorial approaches with chimeric antigen receptors, antibodies, and oncolytic virus technologies. The company works in partnership with National Cancer Centre, Singapore, Baylor College of Medicine, and Agency for Science, Technology and Research. Tessa Therapeutics is headquartered in Singapore.
For a complete picture of Rovaleucel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
